Potential mortality benefit from secondary prophylaxis following CMV treatment completion may be due to confounding by transplant organ type.
Bradley J GardinerJennifer K ChowDavid R SnydmanPublished in: Transplant infectious disease : an official journal of the Transplantation Society (2019)